Wockhardt’s Zaynich achieves record-breaking 96.8% clinical cure rate in cUTI Phase III trial
Wockhardt Limited has announced a major breakthrough in the treatment of complicated urinary tract infections (cUTI) with its novel antibiotic Zaynich (Zidebactam/Cefepime, WCK 5222). In ... Read More